Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on KYOWA HAKKO KIRIN CO LTD
06/28 KYOWA HAKKO KIRIN CO LTD : ex-dividend day for interim dividend
06/23 PARTNERSHIP AGREEMENT FOR A GEL FORM : Treatment for Psoriasis Vulgaris
06/22 PARTNERSHIP AGREEMENT FOR A GEL FORM : Treatment for Psoriasis Vulgaris(130KB)
06/09 KYOWA HAKKO KIRIN : Pharmaceutical firm boss applauds expansion work
05/25 KYOWA HAKKO KIRIN : Patent Issued for Method of Purifying Protein (USPTO 9650411..
05/22 KYOWA HAKKO KIRIN : FUJIFILM KYOWA KIRIN BIOLOGICS Announces Marketing Authorisa..
05/05 KYOWA HAKKO KIRIN : Kirin, Inc. and Dream Foundation Partner to Serve Adults at ..
04/28 KYOWA HAKKO KIRIN : Submits Application for Approval of Evocalcet (KHK7580) for ..
04/27 KYOWA HAKKO KIRIN : Researchers Submit Patent Application, "RNAi PHARMACEUTICAL ..
04/27 KYOWA HAKKO KIRIN : Submits Application for Approval of Evocalcet (KHK7580) for ..
04/20 KYOWA HAKKO KIRIN : Ultragenyx, Kyowa Hakko Kirin plan a date with the FDA after..
04/18 KYOWA HAKKO KIRIN : Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International ..
04/07 KYOWA HAKKO KIRIN : Announces Positive Results of the Phase 3 Clinical Study of ..
04/07 Ultragenyx and Kyowa Kirin International Announce Positive Data from Pediatri..
04/07 KYOWA HAKKO KIRIN : Announces Positive Results of the Phase 3 Clinical Study of ..
04/06 KYOWA HAKKO KIRIN : "Nucleic Acid That Inhibits Expression of Irf5" in Patent Ap..
04/06 KYOWA HAKKO KIRIN : Investigators from Kyowa Hakko Kirin Co Target Drug Developm..
04/06 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Kirin International Announce Positive D..
03/31 KYOWA HAKKO KIRIN : Matters concerning controlling shareholders(44KB)
03/27 KYOWA HAKKO KIRIN : Announces Top-Line Results of Japanese Phase 3 Clinical Stud..
03/24 KYOWA HAKKO KIRIN : Enters Agreement with AstraZeneca for Development and Commer..
03/23 KYOWA HAKKO KIRIN : Notice regarding allotment of stock acquisition rights (stoc..
03/16 KYOWA HAKKO KIRIN : New Data from Kyowa Hakko Kirin Co Illuminate Findings in Ca..
03/16 KYOWA HAKKO KIRIN : Recent Findings from Kyowa Hakko Kirin Co Provides New Insig..
03/13 Global L-Glutamine (Gln) Market 2017- Kyowa Hakko Kirin, Daesang, Meihua
03/08 The UK High Court of Justice (Patents) Rules in Fujifilm Kyowa Kirin Biologic..
03/06 The UK High Court of Justice (Patents) Rules in Fujifilm Kyowa Kirin Biologic..
02/20 KYOWA HAKKO KIRIN : Notice regarding the revision of the remuneration system for..
02/20 KYOWA HAKKO KIRIN : Notice regarding stock acquisition rights for stock compensa..
02/17 KYOWA HAKKO KIRIN : Notice regarding the revision of the remuneration system for..
02/17 KYOWA HAKKO KIRIN : Notice regarding stock acquisition rights for stock compensa..
02/01 KYOWA HAKKO KIRIN : Establishes Kyowa Kirin Frontier Co., Ltd.
02/01 KYOWA HAKKO KIRIN : Announces Top-Line Results of Phase 3 Clinical Study of KHK7..
01/31 KYOWA HAKKO KIRIN : Notice of Recording of Extraordinary Losses in Non-consolida..
01/31 KYOWA HAKKO KIRIN : Establishes Kyowa Kirin Frontier Co., Ltd.(21KB)
01/31 KYOWA HAKKO KIRIN : Announces Top-Line Results of Phase 3 Clinical Study of KHK7..
01/06 Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation App..
01/05 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Kirin International Announce Marketing ..
2016 KYOWA HAKKO KIRIN CO LTD : ex-dividend day for final dividend
2016 KYOWA HAKKO KIRIN : New Cancer Therapy Findings from Kyowa Hakko Kirin Co. Ltd. ..
2016 KYOWA HAKKO KIRIN : Announces Top-Line Results of Global Phase 3 Trial of KW-600..
2016 KYOWA HAKKO KIRIN : Announces Top-Line Results of Global Phase 3 Trial of KW-600..
2016 KYOWA HAKKO KIRIN : Data from Kyowa Hakko Kirin Co. Ltd. Advance Knowledge in Di..
2016 KYOWA HAKKO KIRIN : New Hypercalcemia Study Findings Have Been Reported by Inves..
2016 KYOWA HAKKO KIRIN : Application seeking Approval for Additional formulation of A..
2016 KYOWA HAKKO KIRIN : Launch of LUMICEF for Psoriasis Treatment, in Japan
2016 KYOWA HAKKO KIRIN : Application seeking Approval for Additional formulation of A..
2016 KYOWA HAKKO KIRIN : Launch of LUMICEF® for Psoriasis Treatment, in Japan
2016 KYOWA HAKKO KIRIN : Announces Positive Interim Data from Phase 2 Study of KRN23 ..
2016 KYOWA HAKKO KIRIN : Announces Positive Interim Data from Pediatric and Adult Pha..
2016 KYOWA HAKKO KIRIN : Announces Positive Interim Data from Pediatric and Adult Pha..
2016 KYOWA HAKKO KIRIN : Announces Positive Interim Data from Phase 2 Study of KRN23 ..
2016 Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the ..
2016 KYOWA HAKKO KIRIN : Reports Summarize Colon Cancer Study Results from Kyowa Hakk..
2016 L-Tyrosine Market 2016 - Ajinomoto, Kyowa Hakko Kogyo, Douglas Laboratories, ..
2016 Kyowa Hakko Kirin Announced Kyowa Medex Acquired approval for Insurance Cover..
2016 KYOWA HAKKO KIRIN : Announced Kyowa Medex Acquired approval for Insurance Covera..
2016 KYOWA HAKKO KIRIN : LUMICEF® approved in Japan(112KB)
2016 KYOWA HAKKO KIRIN : US Food and Drug Administration Granted Breakthrough Therapy..
2016 KYOWA HAKKO KIRIN CO LTD : ex-dividend day for interim dividend
2016 KYOWA HAKKO KIRIN : Announces Preliminary Results from Pivotal Phase 2 Study of ..
2016 KYOWA HAKKO KIRIN : Bardoxolone Methyl (RTA 402) Data Show Improvement in Renal ..
2016 KYOWA HAKKO KIRIN : BioWa Announces Office Relocation to Princeton, NJ and appoi..
2016 KYOWA HAKKO KIRIN : Matters concerning controlling shareholders(44KB)
2016 KYOWA HAKKO KIRIN : Notice regarding allotment of stock acquisition rights (stoc..
2016 KYOWA HAKKO KIRIN : Initiation of Operations for Drug Product Manufacturing Faci..
2016 KYOWA HAKKO KIRIN : AstraZeneca sells drug for $70 million as divestment drive c..
2016 KYOWA HAKKO KIRIN : Change of Representative Directors at Kyowa Medex(31KB)
2016 KYOWA HAKKO KIRIN : Notice regarding stock acquisition rights for the purpose of..
2016 KYOWA HAKKO KIRIN : Announces FY2016-2020 Mid-term Business Plan(123KB)
2016 KYOWA HAKKO KIRIN : Appendix to the Consolidated Financial Summary Fiscal 2015(1..
2016 KYOWA HAKKO KIRIN : Consolidated Financial Summary Fiscal 2015(221KB)
2016 KYOWA HAKKO KIRIN : Results Presentation Fiscal 2015(1,924KB)
2016 KYOWA HAKKO KIRIN : Change in the Company Name of Western Pharmaceutical Subsidi..
2016 KYOWA HAKKO KIRIN : BioWa opens POTELLIGENT® Technology license to customers for..
1  2  3Next
Financials ( JPY)
Sales 2017 347 272 M
EBIT 2017 -
Net income 2017 20 660 M
Finance 2017 47 522 M
Yield 2017 1,33%
P/E ratio 2017 50,58
P/E ratio 2018 42,99
EV / Sales 2017 2,99x
EV / Sales 2018 2,87x
Capitalization 1 087 248 M
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | 4151 | JP3256000005 | 4-Traders
Technical analysis trends KYOWA HAKKO KIRIN CO LTD
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 2 247  JPY
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Nobuo Hanai President & Representative Director
Yoichi Sato Director, Managing Executive Officer, GM-R&D
Kazuyoshi Tachibana Director & Managing Executive Officer
Toshifumi Mikayama Director & Managing Executive Officer
Koichiro Nishikawa Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO LTD18.85%9 707
ABBVIE15.81%115 419
MERCK KGAA-0.68%14 809
JAZZ PHARMACEUTICALS PLC47.90%9 690
CONVATEC GROUP31.77%7 834
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO21.95%5 029